This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock FSDC vs. MOR, GMTX, CALT, MENS, ZYME, SBTX, MBX, AVTE, NLTX, and CYBNShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Jyong Biotech (MENS), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). FS Development vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Jyong Biotech Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin MorphoSys (NASDAQ:MOR) and FS Development (NASDAQ:FSDC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Which has preferable earnings & valuation, MOR or FSDC? FS Development has lower revenue, but higher earnings than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45FS DevelopmentN/AN/AN/AN/AN/A Does the media favor MOR or FSDC? In the previous week, MorphoSys' average media sentiment score of 0.00 equaled FS Development'saverage media sentiment score. Company Overall Sentiment MorphoSys Neutral FS Development Neutral Is MOR or FSDC more profitable? FS Development has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. FS Development's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% FS Development N/A N/A N/A Do insiders & institutionals believe in MOR or FSDC? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 89.8% of FS Development shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryFS Development beats MorphoSys on 4 of the 6 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$761.35M$784.96M$5.59B$9.53BDividend YieldN/A4.84%4.73%4.14%P/E RatioN/A1.3028.9123.88Price / SalesN/A25.05445.5998.82Price / CashN/A19.5635.6858.35Price / BookN/A6.478.165.60Net IncomeN/A-$4.35M$3.25B$265.26M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$60.83+1.7%N/A+42.8%$761.35MN/A0.00N/AMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.80+0.5%N/A+39.6%$2.59BN/A-59.8030CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180MENSJyong BiotechN/A$17.96+14.6%N/AN/A$1.19BN/A0.0031Gap DownZYMEZymeworks3.0461 of 5 stars$12.94-4.2%$21.00+62.3%+25.4%$901.70M$93.38M-8.63460Upcoming EarningsSBTXSilverback TherapeuticsN/A$17.75-3.3%N/A+86.5%$640.03MN/A-7.3383High Trading VolumeMBXMBX Biosciences2.7862 of 5 stars$15.49+3.5%$37.57+142.6%N/A$517.74MN/A0.0036News CoverageAnalyst ForecastGap UpHigh Trading VolumeAVTEAerovate TherapeuticsN/A$7.75-6.4%N/A-88.0%$224.63MN/A-2.5920News CoverageUpcoming EarningsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$21.68-4.6%N/A-45.1%$203.75MN/A-6.9790CYBNCybin3.0298 of 5 stars$7.30-3.6%$85.00+1,064.4%N/A$172.21MN/A-1.6750News CoveragePositive News Related Companies and Tools Related Companies MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Jyong Biotech Competitors Zymeworks Competitors Silverback Therapeutics Competitors MBX Biosciences Competitors Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors Cybin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
